Search Thermo Fisher Scientific
Search Thermo Fisher Scientific
Gene editing technologies are becoming increasingly important for research and applied uses. Many of our genome editing technologies, including both TAL effectors and CRISPR-Cas9 systems, are available under license for use in a variety of commercial applications, including research services, contract manufacturing services, therapeutics and therapeutic bioproduction, vaccines, diagnostics, animal health, biofuels, and quality assurance/quality control.
Submit an inquiry below to discuss how we might work together.
With over a decade of experience in developing innovative tools for genome editing, we have designed a novel, programmable TAL-based enzyme, Invitrogen TALXcell nuclease, for use in therapeutic development for CAR-T, NK and allogenic (iPSC) targets. The TALXcell platform has comparable performance as CRISPR-Cas9, but without some of the common limitations of that system.
The TALXcell nuclease consists of a DNA binding domain that is specifically engineered to target your site of interest and that is fused with a highly effective nuclease to cleave the DNA.
To discuss commercial opportunities with our TALXcell genome editing platform, please contact us at outlicensing@thermofisher.com.
GeneArt TALs provide custom DNA-binding proteins for accurate DNA targeting and precise gene editing and gene regulation, enabling users to target any locus in the genome.
The Thermo Fisher Scientific team has clarified a path for users to move confidently forward with GeneArt TALs in research and applied markets, by compiling a powerful intellectual property (IP) portfolio that includes not only the foundational IP originating from the University of Minnesota, Iowa State University, and Martin-Luther-Universitat Halle-Wittenberg, but also IP originating from Thermo Fisher Scientific, Cellectis AS, and others.
Commercial licensing under this broad IP portfolio is available for most applied uses, including transgenic animal services, animal health, quality assurance/quality control, and production of biological materials, chemicals, and compounds for uses in a diverse range of applications.
Please contact us at outlicensing@thermofisher.com or visit TAL-Based Genome Editing to learn more.
The simplicity and flexibility of Invitrogen CRISPR-Cas9 systems are revolutionizing the field of genome editing. Learn more about CRISPR-Based Genome Editing
To discuss commercial opportunities with our CRISPR-Cas products, please contact us at outlicensing@thermofisher.com.
RNAi has proven to be a specific, potent and highly successful approach for loss-of-function studies in virtually all eukaryotic organisms. We offer Stealth RNAi technology for all research applications and additionally for commercial uses, including therapeutics, in conjunction with a commercial use license from Thermo Fisher Scientific. Stealth RNAi technology utilizes a proprietary structure, which uses modified chemical bases in a unique 25-base format. Learn more about RNAi
To discuss commercial opportunities with our RNAi products, please contact us at outlicensing@thermofisher.com.
With over a decade of experience in developing innovative tools for genome editing, we have designed a novel, programmable TAL-based enzyme, Invitrogen TALXcell nuclease, for use in therapeutic development for CAR-T, NK and allogenic (iPSC) targets. The TALXcell platform has comparable performance as CRISPR-Cas9, but without some of the common limitations of that system.
The TALXcell nuclease consists of a DNA binding domain that is specifically engineered to target your site of interest and that is fused with a highly effective nuclease to cleave the DNA.
To discuss commercial opportunities with our TALXcell genome editing platform, please contact us at outlicensing@thermofisher.com.
GeneArt TALs provide custom DNA-binding proteins for accurate DNA targeting and precise gene editing and gene regulation, enabling users to target any locus in the genome.
The Thermo Fisher Scientific team has clarified a path for users to move confidently forward with GeneArt TALs in research and applied markets, by compiling a powerful intellectual property (IP) portfolio that includes not only the foundational IP originating from the University of Minnesota, Iowa State University, and Martin-Luther-Universitat Halle-Wittenberg, but also IP originating from Thermo Fisher Scientific, Cellectis AS, and others.
Commercial licensing under this broad IP portfolio is available for most applied uses, including transgenic animal services, animal health, quality assurance/quality control, and production of biological materials, chemicals, and compounds for uses in a diverse range of applications.
Please contact us at outlicensing@thermofisher.com or visit TAL-Based Genome Editing to learn more.
The simplicity and flexibility of Invitrogen CRISPR-Cas9 systems are revolutionizing the field of genome editing. Learn more about CRISPR-Based Genome Editing
To discuss commercial opportunities with our CRISPR-Cas products, please contact us at outlicensing@thermofisher.com.
RNAi has proven to be a specific, potent and highly successful approach for loss-of-function studies in virtually all eukaryotic organisms. We offer Stealth RNAi technology for all research applications and additionally for commercial uses, including therapeutics, in conjunction with a commercial use license from Thermo Fisher Scientific. Stealth RNAi technology utilizes a proprietary structure, which uses modified chemical bases in a unique 25-base format. Learn more about RNAi
To discuss commercial opportunities with our RNAi products, please contact us at outlicensing@thermofisher.com.